Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endo

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endo Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/07/2015, Revision: 49, Status: Authorised Wil je het laatste nieuws in jouw mailbox ontvangen? Meld je dan aan voor de nieuwsbrief. Volg ons! Nieuwsbrief Twitter Facebook Stel jouw vraag aan de redactie! Naam E-mail * Bericht * Handige Sites De Duurzame Wereld Zonne-energieSector WindenergieSector Autoliefhebber.eu I Ondernemer De Fiere Fries  Vlaams Nieuws De Nederlandse Vereniging   De OnderwijsSector CryptoSector BitcoinSector CardanoSector EthereumSector TerraSector StablecoinSector Privacybeleid Lees verder Wordt geladen...